| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hypoplastic Left Heart Syndrome | D018636 | 1 associated lipids |
| Cryptogenic Organizing Pneumonia | D018549 | 3 associated lipids |
| Ventricular Dysfunction, Left | D018487 | 33 associated lipids |
| Lichen Sclerosus et Atrophicus | D018459 | 2 associated lipids |
| Vasculitis, Leukocytoclastic, Cutaneous | D018366 | 5 associated lipids |
| Hutchinson's Melanotic Freckle | D018327 | 2 associated lipids |
| Angiofibroma | D018322 | 2 associated lipids |
| Cervical Intraepithelial Neoplasia | D018290 | 1 associated lipids |
| Seminoma | D018239 | 2 associated lipids |
| Smooth Muscle Tumor | D018235 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Albano L et al. | OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. | 2013 | Transplantation | pmid:23982340 |
| Cacciarelli TV et al. | An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1999 | Transplantation | pmid:10507484 |
| Marcos A et al. | Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. | 2004 | Transplantation | pmid:15480160 |
| Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
| Burroughs TE et al. | Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. | 2007 | Transplantation | pmid:17452891 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Burke GW et al. | Advances in pancreas transplantation. | 2004 | Transplantation | pmid:15201688 |
| Garrity ER and Mehra MR | An update on clinical outcomes in heart and lung transplantation. | 2004 | Transplantation | pmid:15201689 |
| Pfitzmann R et al. | Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. | 2003 | Transplantation | pmid:12865798 |
| First MR and Fitzsimmons WE | New drugs to improve transplant outcomes. | 2004 | Transplantation | pmid:15201693 |
| Moss MC et al. | Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? | 2014 | Transplantation | pmid:24492429 |
| Wozniak LJ et al. | Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. | 2015 | Transplantation | pmid:26038872 |
| Fridell JA et al. | Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. | 2006 | Transplantation | pmid:16906038 |
| Boldt A et al. | The influence of immunosuppressive drugs on T- and B-cell apoptosis via p53-mediated pathway in vitro and in vivo. | 2006 | Transplantation | pmid:16906043 |
| Kuypers DR et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. | 2010 | Transplantation | pmid:20555228 |
| Narayanan M et al. | Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. | 2013 | Transplantation | pmid:23423268 |
| Gaber AO et al. | Acute rejection characteristics from a prospective, randomized, double-blind, placebo-controlled multicenter trial of early corticosteroid withdrawal. | 2013 | Transplantation | pmid:23423269 |
| Moffatt SD et al. | Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. | 1999 | Transplantation | pmid:10342309 |
| Guethoff S et al. | Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. | 2013 | Transplantation | pmid:23423270 |
| Miyakoshi S et al. | Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. | 2007 | Transplantation | pmid:17700155 |
| Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
| Fujita T et al. | Prolonged survival of rat skin allograft by treatment with FK506 ointment. | 1997 | Transplantation | pmid:9326422 |
| Yoshihara S et al. | Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. | 2004 | Transplantation | pmid:15077022 |
| Jain AB et al. | Pregnancy after kidney and kidney-pancreas transplantation under tacrolimus: a single center's experience. | 2004 | Transplantation | pmid:15077034 |
| Huang E et al. | Alemtuzumab induction in deceased donor kidney transplantation. | 2007 | Transplantation | pmid:17984833 |
| Jain A et al. | Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection. | 2014 | Transplantation | pmid:25285953 |
| Yin DP et al. | Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. | 2001 | Transplantation | pmid:11391223 |
| Bruce DS et al. | Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. | 2001 | Transplantation | pmid:11726823 |
| Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Sanchez-Campos S et al. | Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. | 1998 | Transplantation | pmid:9679826 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Egeland EJ et al. | High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. | 2017 | Transplantation | pmid:28452920 |
| Hsiau M et al. | Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. | 2011 | Transplantation | pmid:21857278 |
| Yates CJ et al. | Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. | 2013 | Transplantation | pmid:23902993 |
| Jordan ML et al. | Long-term results of pancreas transplantation under tacrolius immunosuppression. | 1999 | Transplantation | pmid:10075592 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
| Platz KP et al. | Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518975 |
| Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
| Kaplan B et al. | Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. | 1996 | Transplantation | pmid:8900321 |
| Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
| Ciancio G et al. | Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. | 2011 | Transplantation | pmid:21107305 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
| Reddy KS et al. | Simultaneous kidney-pancreas transplantation without antilymphocyte induction. | 2000 | Transplantation | pmid:10653379 |
| Nobori S et al. | Long-term acceptance of fully allogeneic cardiac grafts by cotransplantation of vascularized thymus in miniature swine. | 2006 | Transplantation | pmid:16421473 |
| Yu S et al. | Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. | 2006 | Transplantation | pmid:16421475 |
| Borrows R et al. | Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. | 2006 | Transplantation | pmid:16421488 |
| Arzouk N et al. | Interaction between tacrolimus and fumagillin in two kidney transplant recipients. | 2006 | Transplantation | pmid:16421493 |
| Muraki T et al. | Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. | 1998 | Transplantation | pmid:9583878 |
| Kadry Z et al. | Kaposi's sarcoma in liver transplant recipients on FK506. | 1998 | Transplantation | pmid:9583882 |
| First MR et al. | New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. | 2013 | Transplantation | pmid:23619735 |
| Luan FL et al. | New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. | 2011 | Transplantation | pmid:21242885 |
| Opelz G | Comparison of FK506 and cyclosporine. | 1996 | Transplantation | pmid:8830844 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Ninova D et al. | Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin. | 2004 | Transplantation | pmid:15316360 |
| Ho ET et al. | Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. | 2013 | Transplantation | pmid:23542469 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Shapiro R et al. | Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. | 2008 | Transplantation | pmid:18431232 |
| Porrini E et al. | Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. | 2008 | Transplantation | pmid:18431233 |
| Veroux M et al. | Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. | 2012 | Transplantation | pmid:22298033 |
| Naesens M et al. | Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. | 2008 | Transplantation | pmid:18431234 |
| Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Inoue T et al. | Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. | 2000 | Transplantation | pmid:11003356 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Roelen DL et al. | Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. | 1993 | Transplantation | pmid:7687397 |
| Holt S and Moore K | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907407 |
| Yang H et al. | Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. | 2002 | Transplantation | pmid:11907415 |
| Klein IH et al. | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907418 |
| St A Nunes FA and Lucey MR | Searching for a balance when applying immunosuppression after liver transplantation. | 2001 | Transplantation | pmid:11258425 |
| Ringe B et al. | A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. | 2001 | Transplantation | pmid:11258429 |
| Podesser BK et al. | Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. | 2005 | Transplantation | pmid:15714171 |
| Cantarovich D et al. | Switching from cyclosporine to tacrolimus in patients with chronic transplant dysfunction or cyclosporine-induced adverse events. | 2005 | Transplantation | pmid:15714172 |
| Nguyen L et al. | Conversion from tacrolimus/mycophenolic acid to tacrolimus/leflunomide to treat cutaneous warts in a series of four pediatric renal allograft recipients. | 2012 | Transplantation | pmid:22960763 |
| Apanay DC et al. | Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. | 1994 | Transplantation | pmid:7524202 |
| Steinmüller TM et al. | The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. | 1994 | Transplantation | pmid:7524203 |
| Singh N et al. | Infectious complications in liver transplant recipients on tacrolimus. Prospective analysis of 88 consecutive liver transplants. | 1994 | Transplantation | pmid:7524204 |
| Ochiai T et al. | Studies of the effects of FK506 on renal allografting in the beagle dog. | 1987 | Transplantation | pmid:2447688 |
| Thomas PG et al. | Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. | 2007 | Transplantation | pmid:17565326 |
| Ochiai T et al. | Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. | 1987 | Transplantation | pmid:2447689 |
| Sonoda T et al. | Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. | 2003 | Transplantation | pmid:12548123 |
| Jain A et al. | The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. | 2003 | Transplantation | pmid:12698091 |
| Egashira K et al. | Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. | 2003 | Transplantation | pmid:12698101 |
| Hu H et al. | Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling. | 2003 | Transplantation | pmid:12698107 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Peng Y et al. | Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. | 2013 | Transplantation | pmid:23263506 |
| Kuypers DR et al. | Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. | 2013 | Transplantation | pmid:23263559 |
| Bendahan J et al. | The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. | 1994 | Transplantation | pmid:7511255 |
| White M et al. | Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. | 2006 | Transplantation | pmid:17006323 |
| Chavin KD et al. | Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. | 1994 | Transplantation | pmid:7511258 |
| Wissing KM et al. | Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. | 2006 | Transplantation | pmid:17006324 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |